Clinical trials: Nerve Degeneration
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Parkinson's Disease
Early Parkinson's Disease Monotherapy With CVN424
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD).
- Trial name
- NCT06006247
- Testing
- CVN424 150 mg
- Where
- 42 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cerevance Beta, Inc.
Parkinson Disease, Physical Activity
Neuroplasticity in Parkinson´s Disease After Training
This project aims to determine the effects of the HiBalance program on neuroplastic changes in people with mild to moderate Parkinson´s disease.
- Conditions
- Parkinson Disease, Physical Activity, Gait Disorders, Neurologic, Neural Degeneration
- Trial name
- BETA-PD (NCT03213873)
- Testing
- HiBalance, Speech and communication therapy
- Where
- Sweden
- Volunteers
- 95 people
- Sponsor
- Karolinska Institutet
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Glaucoma, Macular Degeneration
BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases
The purpose of this research study is to better understand the impact of visual impairment caused by different eye diseases on the ability to perform daily activities and compare it to that in patients without eye diseases.
- Conditions
- Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy
- Trial name
- NCT03318549
- Testing
- Visual Performance tests, Brain-computer interface
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Miami
Parkinson's Disease
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been…
- Trial name
- REPAIR-PD (NCT03815916)
- Testing
- Gold Nanocrystals
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Clene Nanomedicine
Multiple Sclerosis
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
This study will evaluate how improved cerebral blood flow affects the way in which newly formed MS lesions evolve and whether tissue repair is improved.
- Trial name
- perfuseMS (NCT02466074)
- Testing
- Acetazolamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Progressive Supranuclear Palsy
Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some neuroprotective activities and it is hoped that they could be helpful for people with neurodegenerative illnesses such as progressive supranuclear…
- Trial name
- NCT01537549
- Testing
- alpha-lipoic acid and L-acetyl carnitine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Weill Medical College of Cornell University
Kinky Hair Syndrome
Copper Histidine Therapy for Menkes Diseases
Menkes Disease is a genetic disorder affecting the metabolism of copper. Patient with this disease are both physically and mentally retarded. Menkes disease is usually first detected in the first 2-3 months of life.
- Trial name
- NCT00001262
- Testing
- Copper Histidine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Niemann-Pick Disease, Type C
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
Background: Niemann-Pick disease type C (NPC) is a genetic disorder that results in progressive loss of nervous system function by affecting the membranes of nerve cells. There is no known cure for NPC.
- Trial name
- NCT00975689
- Testing
- N-Acetyl Cysteine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT00818389
- Testing
- Lithium Carbonate, Riluzole
- Where
- 37 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital